The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.

Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.

A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.

A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.

AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.

Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.